Drug Profile


Alternative Names: Chemically modified tetracycline 3; CMT-3; COL-3; Metastat; NSC 683551

Latest Information Update: 14 Apr 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator State University of New York at Stony Brook
  • Developer CollaGenex Pharmaceuticals
  • Class Anti-inflammatories; Antiacnes; Antineoplastics; Small molecules; Tetracyclines
  • Mechanism of Action Matrix metalloproteinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Acne; Acute lung injury; Cardiovascular disorders; Inflammation; Mycoses; Periodontal disorders; Rosacea

Most Recent Events

  • 11 Apr 2008 CollaGenex Pharmaceuticals has been acquired by Galderma
  • 26 Sep 2007 Discontinued - Phase-II for Rosacea in USA (PO)
  • 26 Sep 2007 Final results from a phase II clinical trial in moderate-to-severe rosacea added to the Skin Disorders therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top